Prabha Raghavan

Russia's Sputnik V vaccine, developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, was granted emergency use authorisation in India in May.

The government had to, for instance, re-open applications for its PLI scheme for medical devices due to certain issues faced in filling up the 28 slots the first time around.

Subject to “subsequent approvals”, enrollment of participants in the country “should soon begin”, said Annapurna Das, Country Head, Sanofi Pasteur India.

If approved by the regulator, ZyCov-D will be the world's first DNA vaccine against infection with SARS-CoV-2.

Zydus Cadila ZyCov-D vaccine: ZyCov-D is a “plasmid DNA” vaccine — or a vaccine that uses a genetically engineered, non-replicating version of a type of DNA molecule known as a 'plasmid'.

While the government said details on the quantity of doses to be imported to India by Cipla are still under consideration, The Indian Express has learnt that the vaccine is initially expected to be provided to India in limited quantities — as donations by the US drug maker.

If you are traveling out of India to study, for a job or for the Tokyo Olympic games, it is likely that you may be asked for a Covid-19 vaccine certificate linked to your passport.

The results of the phase 3 trials come a day before the Hyderabad company’s scheduled meeting with the World Health Organization (WHO), where it is expected to submit its proposal for an Emergency Use Listing of the vaccine.

Trials in the UK have found a monoclonal antibody cocktail effective in some patients with severe Covid-19. What is this treatment, how does it compare with plasma therapy, and how much promise does it hold?

Companies with logistics experience including Flipkart and Dunzo have announced their consortia under Telangana’s drone delivery scheme to develop and execute drone deliveries there.

The Maryland-headquartered company said its vaccine had demonstrated 100 per cent protection in late-stage trials against moderate and severe disease caused by SARS-CoV-2 — a boost for the prospects of its Indian version, Covovax.

Going by the 80 per cent coverage strategy, the government would have to plan for enough vaccines to cover 104 million children to effectively protect this cohort.

Ocugen, Bharat Biotech’s Covaxin partner in the US, “will no longer pursue an Emergency Use Authorization” of the vaccine in that country, the American clinical stage biopharmaceutical company told Nasdaq on Thursday.

Sources at the IT Ministry said though the issue had been handled for now, CERT-In, with help of other domestic and global cybersecurity experts, was checking the entire CoWin platform once again to ensure there were no vulnerabilities.

The United States has decided not to give emergency use authorisation (EUA) to Bharat Biotech's Covid-19 vaccine, Covaxin. Does this mean there is something wrong with the vaccine?

When the Centre began vaccination in January, it procured 11 million doses of Covishield at Rs 200 each excluding taxes, and about 5.5 million doses of Covaxin at Rs 206 each excluding taxes. However, the prices were later negotiated downwards to Rs 150 per dose.

India is considering whether people can be given a mix of different Covid-19 vaccine doses. What can be the merits of such a programme, and what are the concerns? Which other countries are trying this?

With smaller hospitals in non-metros facing difficulties procuring vaccines, AHPI has facilitated efforts to negotiate with vaccine makers on behalf of some of its members.

India has placed an advance order for 300 million doses of Corbevax. How does this Covid-19 vaccine work, and how does it differ from others? What could the order mean for India’s vaccination programme?

The US will allocate doses to India based on factors such as the country’s vaccination plans, State Department Coordinator for Global Covid-19 Response Gayle E Smith said.

The company on Friday received Drug Controller General of India Dr V G Somani's permission to manufacture batches of Sputnik V “for test and analysis”, a source close to the development told The Indian Express on condition of anonymity.

It is significant that the government has put its money on a novel platform for a Covid-19 vaccine that is yet to receive regulatory approval.

The move, which would make it easier for companies to bring their vaccines to India, follows similar demands raised by, among others, Pfizer and Cipla during negotiations to supply imported vaccines to the country.

The testing may be carried out both using vaccines that are currently available in the country, and those that are in the pipeline.